Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra long-acting β2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma.
(2013) In Therapeutic Advances in Respiratory Disease 7(5). p.264-271- Abstract
- Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β2-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This single-dose crossover study was conducted to investigate and compare with formoterol the bronchodilatory and systemic effects, tolerability and safety of AZD3199, a novel ultra-long-acting β2-agonist (uLABA).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4006265
- author
- Bjermer, Leif LU ; Rosenborg, Johan ; Bengtsson, Thomas and Lötvall, Jan
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Therapeutic Advances in Respiratory Disease
- volume
- 7
- issue
- 5
- pages
- 264 - 271
- publisher
- SAG
- external identifiers
-
- pmid:23907810
- wos:000336024400002
- scopus:84884570872
- pmid:23907810
- ISSN
- 1753-4666
- DOI
- 10.1177/1753465813497527
- language
- English
- LU publication?
- yes
- id
- 53c3e011-6b31-4fb7-a9de-9d42685836c1 (old id 4006265)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23907810?dopt=Abstract
- date added to LUP
- 2016-04-01 10:16:56
- date last changed
- 2022-02-17 08:32:55
@article{53c3e011-6b31-4fb7-a9de-9d42685836c1,
abstract = {{Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β2-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This single-dose crossover study was conducted to investigate and compare with formoterol the bronchodilatory and systemic effects, tolerability and safety of AZD3199, a novel ultra-long-acting β2-agonist (uLABA).}},
author = {{Bjermer, Leif and Rosenborg, Johan and Bengtsson, Thomas and Lötvall, Jan}},
issn = {{1753-4666}},
language = {{eng}},
number = {{5}},
pages = {{264--271}},
publisher = {{SAG}},
series = {{Therapeutic Advances in Respiratory Disease}},
title = {{Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra long-acting β2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma.}},
url = {{http://dx.doi.org/10.1177/1753465813497527}},
doi = {{10.1177/1753465813497527}},
volume = {{7}},
year = {{2013}},
}